Variable | Discovery cohort | Validation cohort | P value | ||
---|---|---|---|---|---|
Total, N | 117 | Â | 74 | Â | Â |
Age | Â | Â | Â | Â | Â |
Mean (range) | 49.03 (25–77) |  | 48.58 (27–72) |  | 0.769 |
Race | Â | Â | Â | Â | 0.414 |
White | 87 | 74.35% | 53 | 71.62% | Â |
Asian | 10 | 8.55% | 3 | 4.05% | Â |
Black | 9 | 7.69% | 9 | 12.16% | Â |
Unknown | 11 | 9.41% | 8 | 10.81% | Â |
Native Hawaiian or other Pacific Islander | 0 | 0 | 1 | 1.35% | Â |
Lesion type | Â | Â | Â | Â | 0.309 |
Multiple masses | 65 | 55.56% | 33 | 44.59% | Â |
Multiple NME | 5 | 4.27% | 6 | 8.11% | Â |
Single mass | 43 | 36.75% | 30 | 40.54% | Â |
Single NME | 4 | 3.42% | 5 | 6.76% | Â |
HER2 | Â | Â | Â | Â | 0.974 |
Positive | 30 | 25.64% | 18 | 24.32% | Â |
Negative | 87 | 74.36% | 56 | 75.68% | Â |
HR | Â | Â | Â | Â | 0.959 |
Positive | 71 | 60.68% | 46 | 62.16% | Â |
Negative | 46 | 39.32% | 28 | 37.84% | Â |
SBR grade | Â | Â | Â | Â | 0.592 |
I (Low) | 3 | 2.56% | 2 | 2.70% | Â |
II (Intermediate) | 36 | 30.77% | 17 | 22.97% | Â |
III (High) | 77 | 65.81% | 55 | 74.32% | Â |
Unknown | 1 | 0.85% | 0 | 0 | Â |
MRLD | Â | Â | Â | Â | Â |
Mean (range) | 4.02 (0.44–15) |  | 4.73 (1.6–13.2) |  | 0.049 |
pCR | Â | Â | Â | Â | 1.000 |
pCR | 36 | 30.77% | 23 | 31.08% | Â |
non-pCR | 81 | 69.23% | 51 | 68.92% | Â |
Treatment arm* | Â | Â | Â | Â | 0.351 |
Paclitaxel | 23 | 19.66% | 15 | 20.27% | Â |
Paclitaxel + Trastuzumab | 3 | 2.56% | 1 | 1.35% |  |
Paclitaxel + MK-2206 | 11 | 9.40% | 6 | 8.11% |  |
Paclitaxel + Trastuzumab + MK-2206 | 9 | 7.69% | 2 | 2.70% |  |
Paclitaxel + Trebananib | 27 | 23.08% | 12 | 16.22% |  |
Paclitaxel + Trastuzumab + Trebananib | 2 | 1.71% | 4 | 5.41% |  |
Trastuzumab + Pertuzumab | 10 | 8.55% | 4 | 5.41% |  |
Paclitaxel + Trastuzumab + Pertuzumab | 6 | 5.13% | 4 | 5.41% |  |
Paclitaxel + Ganitumab | 24 | 20.51% | 20 | 27.03% |  |
Paclitaxel + Ganetespib | 2 | 1.71% | 3 | 4.05% |  |
Paclitaxel + Neratinib | 0 | 0 | 2 | 2.70% |  |
Unknown | 0 | 0 | 1 | 1.35% | Â |